By combining state-of-the-art nanotechnology and classical coordination chemistry, Jie is developing new generation nanoadjuvants with improved efficacy and safety over current market Alum-based adjuvants (which do not activate cellular mediated immunity). The core technology has been which has been patented (PCT/AU2021/900753) and licensed to a pharmaceutics company N4Pharm, who has launched ‘NUVEC’, an adjuvant delivery system for cancer vaccines.

Project members

Researchers

Dr Jie Tang

Postdoctoral Research Fellow
Yu Group